The Prospective Non-randomized Case-control Study From Real-world Lung Cancer Patients

Not Applicable

• Conditions: Diseases of the respiratory system

• Registration Number: KCT0006322
• Lead Sponsor: Samsung Medical Center

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 12 July 2021

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 800

Inclusion Criteria

1.Immunotherapy group
? Male and female patients must be at least 19 years of age.
? Patients with histologically confirmed NSCLC
? Patients on palliative therapy for recurrence after surgery or de novo advanced and metastatic disease
? Patients receiving reimbursed immunotherapy as a second-line therapy (in case of targeted therapy, patients receiving immunotherapy after targeted therapy-platinum-based chemotherapy)
? Patients who provided written informed consent for the study (including the secondary use of the study data and sharing with third parties)

Exclusion Criteria

1. Immunochemotherapy group
? Patients receiving immunotherapy without reimbursement
? Patients who do not provide consent to the study
2. Cytotoxic chemotherapy group
? Patients receiving cytotoxic chemotherapy without reimbursement
? Patients who do not provide consent to the study

Study & Design

• Study Type: Observational Study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Progression-free survival;Overall-survival

Secondary Outcome Measures

Name	Time	Method
Response rate;Disease control rate;Duration of response;Hyper-progression